{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:48:32Z","timestamp":1776091712333,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.heliyon.2023.e16169","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T07:31:30Z","timestamp":1684135890000},"page":"e16169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis"],"prefix":"10.1016","volume":"9","author":[{"given":"Hafiza Arooba","family":"Riaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dur E.","family":"Nishwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameer","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9637-6365","authenticated-orcid":false,"given":"Braira","family":"Wahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8207-0675","authenticated-orcid":false,"given":"Akhtar","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babita","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Idrees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e16169_bib1","series-title":"Hepatitis C","author":"Basit","year":"2020"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e16169_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4254\/wjh.v10.i1.88","article-title":"Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience","volume":"10","author":"Kaneko","year":"2018","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.heliyon.2023.e16169_bib3","series-title":"Direct-Acting Antivirals in Chronic Hepatitis C Infection with Liver Cirrhosis","author":"Gayam","year":"2019"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e16169_bib4","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/apt.14593","article-title":"Direct\u2010acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study","volume":"47","author":"Singer","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e16169_bib5","first-page":"735","article-title":"Next big threat for Pakistan hepatocellular carcinoma (HCC)","volume":"66","author":"Parkash","year":"2016","journal-title":"J. Pak. Med. Assoc."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e16169_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12879-018-3125-6","article-title":"Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study","volume":"18","author":"Lanini","year":"2018","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e16169_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e16169_bib8","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/MEG.0000000000000895","article-title":"Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience","volume":"29","author":"Wahid","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e16169_bib9","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/lt.25804","article-title":"Drug\u2010induced liver injury after liver transplantation","volume":"26","author":"Jim\u00e9nez\u2010P\u00e9rez","year":"2020","journal-title":"Liver Transplant."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e16169_bib10","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1177\/1078155218819742","article-title":"Tamoxifen-induced hepatotoxicity caused by drug interaction with direct-acting antiviral agents for hepatitis C","volume":"25","author":"Wyffels","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e16169_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J. Transl. Int. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e16169_bib12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/0049475520936878","article-title":"Hepatitis C treatment in the era of directly acting antivirals: an encouraging scenario","volume":"50","author":"Jain","year":"2020","journal-title":"Trop. Doct."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e16169_bib13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2217\/fvl-2017-0158","article-title":"Poor response to direct-acting antiviral therapy in HCV-infected elderly population: a real-life cohort study based on GeneXpert\u00ae technology","volume":"13","author":"Wahid","year":"2018","journal-title":"Fut. Virol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e16169_bib14","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/jmv.25745","article-title":"Direct\u2010acting antiviral agents in the treatment of chronic hepatitis C\u2014Real\u2010life experience from clinical practices in Pakistan","volume":"92","author":"Mushtaq","year":"2020","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e16169_bib15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40266-017-0515-1","article-title":"Chronic hepatitis C in elderly patients: current evidence with direct-acting antivirals","volume":"35","author":"Jhaveri","year":"2018","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e16169_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5009\/gnl18269","article-title":"High efficacy and safety of flat-dose ribavirin plus sofosbuvir\/daclatasvir in genotype 3 cirrhotic patients","volume":"14","author":"Pellicelli","year":"2020","journal-title":"Gut Liver"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e16169_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-020-05173-4","article-title":"High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia","volume":"13","author":"Butsashvili","year":"2020","journal-title":"BMC Res. Notes"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e16169_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4254\/wjh.v11.i1.1","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review","volume":"11","author":"Desai","year":"2019","journal-title":"World J Hepatol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e16169_bib19","doi-asserted-by":"crossref","first-page":"e3157","DOI":"10.1002\/dmrr.3157","article-title":"Prevalence of diabetes in liver cirrhosis: a systematic review and meta\u2010analysis","volume":"35","author":"Lee","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e16169_bib20","first-page":"10","volume":"1","author":"Ali","year":"2019","journal-title":"The correlation Between Alpha-Fetoprotein and Liver Function Tests"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023033765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023033765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:22:05Z","timestamp":1773397325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023033765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2405844023033765"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16169","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e16169"}}